1 completed. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Completed 1 |
Follow MPS 7: new trials by email Literature Review of MPS 7 trials Research Report on MPS 7
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 3 Study of UX003 Recombinant Human Betaglucuronidase (rhGUS) Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis Type 7 (MPS 7) UX003, Placebo - MPS 7, Sly Syndrome | Phase 3 | Completed | Ultragenyx Pharmaceutical Inc | 12 | 2014-12-01 | 2020-07-30 |
Lysosomal Storage Diseases (1) · Metabolic Diseases (1) · Mucopolysaccharidoses (1) · Mucopolysaccharidosis VII (1) · Rare Diseases (1)
Carbohydrate Metabolism, Inborn Errors (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Connective Tissue Diseases (1) · Disease Attributes (1) · Genetic Diseases, Inborn (1) · Metabolism, Inborn Errors (1) · Mucinoses (1) · Nutritional and Metabolic Diseases (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1) · Skin and Connective Tissue Diseases (1)
Ultragenyx Pharmaceutical Inc (1)
United States (1)
Chester Whitley, MD (1) · Mislen Bauer, MD (1) · Paul Harmatz, MD (1) · Raymond Wang, MD (1)
PMID 29478819, PMID 30467742, PMID 32063397, PMID 33874971, PMID 37415957